Therefore, a significant increase in the number of hepatic CXCR6+ CD8+ T cells might exaggerate damage in the liver parenchyma, aggravate MASH and ultimately, imbalance immunity and weaken liver’s defenses against cancer. The gene discussed is CD8A; the disease is cancer.